Apheresis Equipment Market Forecasts to 2028 – Global Analysis By Product (Apheresis Machine, Disposable Apheresis Kits, Plasma and Component Separator), Procedure, Technology, Distribution Channel, Application, and By Geography

Apheresis Equipment Market Forecasts to 2028 – Global Analysis By Product (Apheresis Machine, Disposable Apheresis Kits, Plasma and Component Separator), Procedure, Technology, Distribution Channel, Application, and By Geography

According to Stratistics MRC, the Global Apheresis Equipment Market is accounted for $2.26 billion in 2022 and is expected to reach $4.35 billion by 2028 growing at a CAGR of 11.5% during the forecast period. Apheresis is a procedure in which blood is temporarily taken from a donor and separated into its components. The necessary components, such as plasma or platelets, are retained and the remaining blood is returned to the donor by transfusion. Platelets are used to treat various diseases and are extracted with apheresis equipment. It finds application in blood banks and the treatment of various medical conditions. In recent years, the introduction of modern apheresis equipment has led to the development of advanced features, such as auto elutriation and fluid flow dynamics, and has enabled the collection of platelets or red blood cells (RBCs) concentrates.

As per the Centers for Disease Control and Prevention (CDC), in 2021, it was estimated that about 37 million (15%) adults in the United States had chronic kidney disease (CKD). Apheresis plays a vital role in blood purification in patients with kidney disorders and drives the market studied. Along with these factors, the increasing product innovations and approvals have been driving market growth.

Market Dynamics:

Driver:

Growing utilization in different types of procedures

There are different types of procedures depending upon the constituents of blood undergoing centrifugation i.e. the components being separated and withdrawn such as Plasma (plasmapheresis), Platelets (plateletpheresis), Leukocytes (leukapheresis), Lymphocytes (lymphopheresis or lymphapheresis) and Red blood cells (erythropheresis). Whereas the procedures also has many therapeutic applications in which the diseased component of the blood is removed while the healthy component is returned back to the patient’s circulation. In addition ti this the procedure can also be used in stem cell harvesting. Apheresis equipment market is growing, this is attributed to increasing usage of this equipment during blood donation also the equipment is used in many diseases such as severe cryoglobulinemia, Guillain-Barre (GB) syndrome, homozygous familial hypercholesterolemia, myasthenia gravis, fulminant Wilson disease etc. In addition to this, apheresis procedure is also used as second line treatment in many other conditions.

Restraint:

High investment

The high financial cost of the apheresis procedure and equipment as well as the huge capital investment required estimated to hinder the market growth. Huge Research and Development costs are entailed for manufacturing the product followed by the marketing costs. The risk associated with apheresis includes a tendency to bleed as the clotting factor is removed, low blood pressure owing to removal of fluids, susceptibility to infections on account of the removal of antibodies, and anticoagulant reactions. The lack of highly trained and competent apheresis operators continues to impede market growth.

Opportunity:

Growing inclination for blood components

Blood is necessary for the human body's health and survival. The demand for blood components is rising on account of the increasing rate of blood transfusions for chronic blood conditions and surgeries, the increasing prevalence of chronic diseases in the elderly population, and rising incidence rates of cancer. According to American red Cross, approximately 29,000 units of red blood cells are needed every day in the U. S. red blood cells are used to cure anemia which develops when your blood lacks enough healthy red blood cells to carry oxygen to body tissues. It affects more than 3 million Americans, according to the National Heart, Lung, and Blood Institute. Platelet transfusions are required for patients with chronic diseases such as liver disease and myelofibrosis. Platelet count tends to decline below normal as this disease advances and platelet function becomes impaired. There’s been increasing demand for platelet-rich plasma owing to the rising number of road accidents and trauma cases, driving the market growth.

Threat:

Disruptions due to pandemic

The global apheresis equipment market is expected to witness substantial growth post-pandemic. The COVID-19 has affected economies and industries in various countries due to lockdowns, travel bans, and business shutdowns. The COVID-19 crisis has overburdened public health systems in many countries and highlighted the strong need for sustainable investment in health systems. As the COVID-19 pandemic progresses, the healthcare industry is expected to see a drop in growth. The life sciences segment thrives due to increased demand for invitro diagnostic products and rising research and development activities worldwide. However, the medical technologies and imaging segment is witnessing drop in sales due to a smaller number of surgeries being carried out and delayed or prolonged equipment procurement.

Covid-19 Impact

The apheresis market was expected to be positively impacted during the COVID-19 pandemic due to the extensive application of plasma therapy to treat patients infected with COVID-19. Furthermore, in August 2020, the US FDA granted emergency use authorization (EUA) for convalescent plasma (CCP) therapy in hospitalized individuals with COVID-19. Also, in April 2020, Terumo BCT Inc. and Marker Therapeutics AG received the FDA approval for the Emergency Use Authorization (EUA) of Terumo BCT’s Spectra Optia Apheresis System combined with Marker Therapeutics’ D2000 Adsorption Cartridge to treat patients aged 18 years and above with confirmed COVID-19 disease.

The centrifugation segment is expected to be the largest during the forecast period

The centrifugation segment is estimated to have a lucrative growth. Centrifugation is an extremely efficacious procedure which facilitates in attaining the extraction rate of the blood plasma up to 80%. The procedure can be carried out as a continuous flow or intermittent flow and necessitates lower rates of the blood flow, enabling it to be executed with the help of central venous access or peripheral venous access. The Continuous Flow centrifugation is capable of operating with simultaneous functions of separating, processing and re-infusing the blood components. The multi-functionality allows for saving time significantly but require two vascular access sites. It is advantageous over the Intermittent Flow centrifugation procedure which involves recurrent cycles of blood drawing, separating, processing and re-infusion. It consumes much longer time using only one vascular access site.

The plasmapheresis (plasma) segment is expected to have the highest CAGR during the forecast period

The plasmapheresis (plasma) segment is anticipated to witness the fastest CAGR growth during the forecast period owing to its use for treating covid patients, increasing autoimmune disorders and neurological diseases. Plasmapheresis is a method for removing blood plasma from the body that involves drawing blood, separating it into plasma and cells, and then restoring the cells into the bloodstream. During the pandemic, plasmapheresis was used to extract convalescent plasma. Plasma from individuals who have recovered from an infection is known as convalescent plasma. Antibodies to the infection virus are present in this plasma. Antibodies are proteins produced by the immune system following an infection that can neutralize or kill the virus while also aiding in recovery, thereby driving the segment growth.

Region with highest share:

Asia Pacific is projected to hold the largest market share during the forecast period. Increasing prevalence of blood disorders requiring plasma and platelet transfusion in the emerging markets of India and China is one of the key factors accounting for this growth in revenue share. The healthcare infrastructure has undergone remarkable changes and upgradation. It has shown readiness in adoption of the advanced technologies and medical devices. It has been home to numerous innovations in the field of novel drug therapeutics and patient-centred treatments. Furthermore, improving healthcare infrastructure and increasing number of healthcare practitioners in the Asia Pacific region is expected to present the industry with a robust growth rate during the forecast period.

Region with highest CAGR:

North America is projected to have the highest CAGR over the forecast period owing to the presence of sophisticated healthcare infrastructure and high patient awareness levels coupled with relatively higher healthcare expenditure. The region is in the forefront of the innovation and developments in the healthcare arena. It benefits from the key industrial players who have headquarters in the states of U.S and Canada. These countries being the focal points of development, the favourable regulatory scenario and the continuous support of the government have played a key role in their development. According to the American Red Cross Society Each year, an estimated 6.8 million people in the U.S. donate blood. Relatively larger number of R&D exercises pertaining to product manufacturing and marketing activities in the region also boosts the market growth.

Key players in the market

Some of the key players profiled in the Apheresis Equipment Market include Asahi Kasei Corporation, B. Braun, Baxter International Inc, Cerus Corporation, Fenwal, Fresenius, Haemonetics, HemaCare, KANEKA MEDIX CORPORATION, Kawasumi Laboratories, Incorporated, Medica S.p.A, Medicap Inc, Terumo BCT, and Therakos.

Key Developments:

In January 2020, Fresenius Kabi, which is a global healthcare company announced expansion of apheresis disposables and plant worth €30 million in Dominican Republic. The plant expansion will help the company to maintain its position as a leading global exporter of apheresis and plasma collecting equipment.

In July 2020, Haemonetics Corporation announced that it had entered into an agreement with Abénex to sell its full-owned subsidiary Inlog Holdings France SAS to the latter company. The transaction is projected to close by the end of the Third quarter of 2020.

In October 2021, Terumo Blood and Cell Technologies expanded its production capacity by opening a new manufacturing facility in Costa Rica worth $60 million USD. The Costa Rica plant will help to expand the production of Spectra Optia Apheresis System besides other products and support its global supply chain spanning 130 countries.

In July 2021, Terumo Blood and Cell Technologies, specialized in blood component, therapeutic apheresis and cellular technologies expanded the functionality of Spectra Optia, therapeutic apheresis, cell processing, and cell collection platform, with an accessory device, the UVA PIT System to perform extracorporeal photopheresis immunotherapy (ECP) procedures at the patient's bedside.

Procedures Covered:
• Erythrocytapheresis (Red Blood Cells)
• Extracorporeal Immunoadsorption (ECI)
• Leukapheresis
• Low-Density Lipoprotein (LDL) Apheresis
• Photopheresis
• Plasmapheresis (Plasma)
• Plateletpheresis (Platelets)
• Therapeutic Cytapheresis Equipment
• Other Procedures

Products Covered:
• Apheresis Machine
• Disposable Apheresis Kits
• Plasma and Component Separator

Technologies Covered:
• Membrane Filtration
• Centrifugation

Distribution Channels Covered:
• Direct
• Retail

Applications Covered:
• Blood Collection
• Therapeutic Purpose

End Users Covered
• Ambulatory Surgical Centers
• Blood Banks/Blood Donation Centers
• Dialysis Centres
• Hospitals & Clinics

Regions Covered:
• North America
US
Canada
Mexico
• Europe
Germany
UK
Italy
France
Spain
Rest of Europe
• Asia Pacific
Japan
China
India
Australia
New Zealand
South Korea
Rest of Asia Pacific
• South America
Argentina
Brazil
Chile
Rest of South America
• Middle East & Africa
Saudi Arabia
UAE
Qatar
South Africa
Rest of Middle East & Africa

What our report offers:
- Market share assessments for the regional and country-level segments
- Strategic recommendations for the new entrants
- Covers Market data for the years 2020, 2021, 2022, 2025, and 2028
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements